JP2016514719A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016514719A5 JP2016514719A5 JP2016503669A JP2016503669A JP2016514719A5 JP 2016514719 A5 JP2016514719 A5 JP 2016514719A5 JP 2016503669 A JP2016503669 A JP 2016503669A JP 2016503669 A JP2016503669 A JP 2016503669A JP 2016514719 A5 JP2016514719 A5 JP 2016514719A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- hydrogen
- independently
- alkylene
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 CC(*)(C=C1)C=Cc2c1c(-c1ncc(*)c(NC3=*C(C)(*)C=NC=C3)n1)n[n]2 Chemical compound CC(*)(C=C1)C=Cc2c1c(-c1ncc(*)c(NC3=*C(C)(*)C=NC=C3)n1)n[n]2 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13160444 | 2013-03-21 | ||
| EP13160444.9 | 2013-03-21 | ||
| PCT/EP2014/055658 WO2014147204A1 (en) | 2013-03-21 | 2014-03-20 | Heteroaryl substituted indazoles |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016514719A JP2016514719A (ja) | 2016-05-23 |
| JP2016514719A5 true JP2016514719A5 (OSRAM) | 2017-04-20 |
Family
ID=47900959
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016503669A Pending JP2016514719A (ja) | 2013-03-21 | 2014-03-20 | ヘテロアリール置換インダゾール |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20160046604A1 (OSRAM) |
| EP (1) | EP2976335A1 (OSRAM) |
| JP (1) | JP2016514719A (OSRAM) |
| CN (1) | CN105164116A (OSRAM) |
| CA (1) | CA2907594A1 (OSRAM) |
| HK (1) | HK1223350A1 (OSRAM) |
| WO (1) | WO2014147204A1 (OSRAM) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA111754C2 (uk) | 2011-10-06 | 2016-06-10 | Байєр Фарма Акцієнгезелльшафт | Заміщені бензиліндазоли для застосування як інгібіторів bub1-кінази для лікування гіперпроліферативних захворювань |
| JP6141866B2 (ja) | 2011-12-21 | 2017-06-07 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ | 置換ベンジルピラゾール類 |
| CA2907730A1 (en) * | 2013-03-21 | 2014-09-25 | Bayer Pharma Aktiengesellschaft | Diaminoheteroaryl substituted indazoles |
| EP2976336A1 (en) * | 2013-03-21 | 2016-01-27 | Bayer Pharma Aktiengesellschaft | 3-heteroaryl substituted indazoles |
| EP3010901B1 (en) | 2013-06-21 | 2017-09-13 | Bayer Pharma Aktiengesellschaft | Heteroaryl substituted pyrazoles |
| JP2016525076A (ja) | 2013-06-21 | 2016-08-22 | バイエル ファーマ アクチエンゲゼルシャフト | 置換されたベンジルピラゾール類 |
| WO2015063003A1 (en) | 2013-10-30 | 2015-05-07 | Bayer Pharma Aktiengesellschaft | Heteroaryl substituted pyrazoles |
| WO2015193339A1 (en) | 2014-06-17 | 2015-12-23 | Bayer Pharma Aktiengesellschaft | 3-amino-1,5,6,7-tetrahydro-4h-indol-4-ones |
| US10350206B2 (en) | 2014-09-19 | 2019-07-16 | Bayer Pharma Aktiengesellschaft | Benzyl substituted indazoles as BUB1 inhibitors |
| WO2016041925A1 (en) * | 2014-09-19 | 2016-03-24 | Bayer Pharma Aktiengesellschaft | Benzyl substituted indazoles |
| CN107406417B (zh) | 2015-01-28 | 2020-06-09 | 拜耳制药股份公司 | 4H-吡咯并[3,2-c]吡啶-4-酮衍生物 |
| CA2989469A1 (en) | 2015-06-17 | 2016-12-22 | Bayer Pharma Aktiengesellschaft | 3-amino-1,5,6,7-tetrahydro-4h-indol-4-ones |
| CA3008393A1 (en) * | 2015-12-16 | 2017-06-22 | Bayer Pharma Aktiengesellschaft | Hetero-1,5,6,7-tetrahydro-4h-indol-4-ones |
| WO2017148995A1 (en) | 2016-03-04 | 2017-09-08 | Bayer Pharma Aktiengesellschaft | 1-(pyrimidin-2-yl)-1h-indazoles having bub1 kinase inhibiting activity |
| WO2017157991A1 (en) | 2016-03-18 | 2017-09-21 | Bayer Pharma Aktiengesellschaft | 1-alkyl-pyrazoles and -indazoles as bub1 inhibitors for the treatment of hyperproliferative diseases |
| WO2017157992A1 (en) | 2016-03-18 | 2017-09-21 | Bayer Pharma Aktiengesellschaft | Annulated pyrazoles as bub1 kinase inhibitors for treating proliferative disorders |
| WO2018122168A1 (en) | 2016-12-29 | 2018-07-05 | Bayer Pharma Aktiengesellschaft | Combinations of bub1 kinase and parp inhibitors |
| WO2018158175A1 (en) | 2017-02-28 | 2018-09-07 | Bayer Pharma Aktiengesellschaft | Combination of bub1 inhibitors |
| ES2924359T3 (es) | 2017-04-11 | 2022-10-06 | Sunshine Lake Pharma Co Ltd | Compuestos de indazol sustituidos con flúor y usos de los mismos |
| WO2018206547A1 (en) | 2017-05-12 | 2018-11-15 | Bayer Pharma Aktiengesellschaft | Combination of bub1 and atr inhibitors |
| WO2018215282A1 (en) | 2017-05-26 | 2018-11-29 | Bayer Pharma Aktiengesellschaft | Combination of bub1 and pi3k inhibitors |
| EP4217070A1 (en) | 2020-09-23 | 2023-08-02 | Scorpion Therapeutics, Inc. | Pyrrolo[3,2-c]pyridin-4-one derivatives useful in the treatment of cancer |
| TW202229282A (zh) | 2020-09-30 | 2022-08-01 | 美商史考皮恩治療有限公司 | 治療癌症之方法 |
| WO2022072645A2 (en) | 2020-09-30 | 2022-04-07 | Scorpion Therapeutics, Inc. | Methods for treating cancer |
| JP2023548657A (ja) | 2020-10-09 | 2023-11-20 | スコーピオン セラピューティクス インコーポレイテッド | がんの処置に使用するための、ｅｇｆｒおよび／またはｈｅｒ２のヘテロ環阻害剤 |
| WO2022094271A1 (en) | 2020-10-30 | 2022-05-05 | Scorpion Therapeutics, Inc. | Methods for treating cancer |
| WO2022098992A1 (en) | 2020-11-05 | 2022-05-12 | Scorpion Therapeutics, Inc. | Use of macrocyclic compounds in methods of treating cancer |
| WO2022197913A1 (en) | 2021-03-18 | 2022-09-22 | Scorpion Therapeutics, Inc. | Bicyclic derivatives which can be used to treat cancer |
| WO2023173083A1 (en) | 2022-03-11 | 2023-09-14 | Scorpion Therapeutics, Inc. | Tetrahydroindole derivatives as egfr and/or her2 inhibtors useful for the treatment of cancer |
| EP4293019A1 (en) * | 2022-06-13 | 2023-12-20 | Netherlands Translational Research Center Holding B.V. | 4-substituted (1h-benzo[d]imidazol-2-yl)-1h-pyrazoles as bub1 inhibitors useful for treating cancers |
| WO2024254298A1 (en) | 2023-06-08 | 2024-12-12 | Scorpion Therapeutics, Inc. | A 1,5-dihydro-4h-pyrrolo[3,2-c] pyridin-4-one for use in the treatment of cancer |
| WO2024254266A1 (en) | 2023-06-08 | 2024-12-12 | Scorpion Therapeutics, Inc. | A 1,5-dihydro-4h-pyrrolo[3,2-c] pyridin-4-one for use in the treatment of cancer |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007065010A2 (en) * | 2005-12-02 | 2007-06-07 | Hif Bio, Inc. | Anti-angiogenesis compounds |
| DE102006027156A1 (de) * | 2006-06-08 | 2007-12-13 | Bayer Schering Pharma Ag | Sulfimide als Proteinkinaseinhibitoren |
| JP2010111624A (ja) * | 2008-11-06 | 2010-05-20 | Shionogi & Co Ltd | Ｔｔｋ阻害作用を有するインダゾール誘導体 |
| UA111754C2 (uk) * | 2011-10-06 | 2016-06-10 | Байєр Фарма Акцієнгезелльшафт | Заміщені бензиліндазоли для застосування як інгібіторів bub1-кінази для лікування гіперпроліферативних захворювань |
| JP6014158B2 (ja) * | 2011-11-28 | 2016-10-25 | コーニンクレッカ フィリップス エヌ ヴェＫｏｎｉｎｋｌｉｊｋｅ Ｐｈｉｌｉｐｓ Ｎ．Ｖ． | 放電ランプの向上されたスポットモード動作 |
| JP6141866B2 (ja) * | 2011-12-21 | 2017-06-07 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ | 置換ベンジルピラゾール類 |
| DE102012200352A1 (de) * | 2012-01-11 | 2013-07-11 | Bayer Intellectual Property Gmbh | Substituierte, annellierte Imidazole und Pyrazole und ihre Verwendung |
| HK1207861A1 (en) * | 2012-05-11 | 2016-02-12 | Bayer Pharma Aktiengesellschaft | Substituted cycloalkenopyrazoles as bub1 inhibitors for the treatment of cancer |
| ES2634014T3 (es) * | 2013-01-30 | 2017-09-26 | Bayer Pharma Aktiengesellschaft | Isotiazoles sustituidos con amino |
| EP2976336A1 (en) * | 2013-03-21 | 2016-01-27 | Bayer Pharma Aktiengesellschaft | 3-heteroaryl substituted indazoles |
| CA2907730A1 (en) * | 2013-03-21 | 2014-09-25 | Bayer Pharma Aktiengesellschaft | Diaminoheteroaryl substituted indazoles |
| EP3010901B1 (en) * | 2013-06-21 | 2017-09-13 | Bayer Pharma Aktiengesellschaft | Heteroaryl substituted pyrazoles |
| JP2016522231A (ja) * | 2013-06-21 | 2016-07-28 | バイエル ファーマ アクチエンゲゼルシャフト | ジアミノヘテロアリール置換ピラゾール類 |
| JP2016525076A (ja) * | 2013-06-21 | 2016-08-22 | バイエル ファーマ アクチエンゲゼルシャフト | 置換されたベンジルピラゾール類 |
| EP3010911A1 (en) * | 2013-06-21 | 2016-04-27 | Bayer Pharma Aktiengesellschaft | Heteroaryl substituted pyrazoles |
| EP3010902A1 (en) * | 2013-06-21 | 2016-04-27 | Bayer Pharma Aktiengesellschaft | Substituted benzylpyrazoles |
-
2014
- 2014-03-20 WO PCT/EP2014/055658 patent/WO2014147204A1/en not_active Ceased
- 2014-03-20 CA CA2907594A patent/CA2907594A1/en not_active Abandoned
- 2014-03-20 EP EP14711968.9A patent/EP2976335A1/en not_active Withdrawn
- 2014-03-20 HK HK16106656.4A patent/HK1223350A1/zh unknown
- 2014-03-20 CN CN201480025220.8A patent/CN105164116A/zh active Pending
- 2014-03-20 US US14/778,733 patent/US20160046604A1/en not_active Abandoned
- 2014-03-20 JP JP2016503669A patent/JP2016514719A/ja active Pending
-
2017
- 2017-03-10 US US15/456,239 patent/US20170275268A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016514719A5 (OSRAM) | ||
| JP2016514718A5 (OSRAM) | ||
| KR102007056B1 (ko) | 과증식성 질환 치료시 Bub1 키나제 저해제로 사용하기 위한 치환된 벤질인다졸 | |
| AU2020355343B2 (en) | Polyheterocyclic modulators of STING (stimulator of interferon genes) | |
| JP2016522232A5 (OSRAM) | ||
| JP2016525075A5 (OSRAM) | ||
| US10590105B2 (en) | 1,3-dihydroxy-phenyl derivatives useful as immunomodulators | |
| JP2015518899A5 (OSRAM) | ||
| JP2016525076A5 (OSRAM) | ||
| JP2019532084A5 (OSRAM) | ||
| JP2016525135A5 (OSRAM) | ||
| JP2019094350A (ja) | 抗癌活性及び抗増殖活性を呈する２−アミノピリミジン−６−オン及び類似体 | |
| JP2015537017A5 (OSRAM) | ||
| JP2017526726A5 (OSRAM) | ||
| JP2016522231A5 (OSRAM) | ||
| JP2020507582A5 (OSRAM) | ||
| JP2014513110A5 (OSRAM) | ||
| JP2018519343A5 (OSRAM) | ||
| KR102609431B1 (ko) | Phd 저해제로서의 활성을 갖는 융합된 바이시클릭 헤테로아릴 유도체 | |
| JP2015514808A5 (OSRAM) | ||
| JP2014510147A5 (OSRAM) | ||
| JP2017538721A5 (OSRAM) | ||
| JP2016526540A5 (OSRAM) | ||
| JP2016514717A5 (OSRAM) | ||
| JP2014513704A5 (OSRAM) |